Imaging method for digestive system cancer using targeted PET scans
Development and Clinical Translation of immunoPET Imaging Probes for Digestive System Carcinoma
NA · RenJi Hospital · NCT06715839
This study is testing a new type of PET scan to see if it can better help doctors find and diagnose cancers in the digestive system.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | RenJi Hospital (other) |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06715839 on ClinicalTrials.gov |
What this trial studies
This study aims to establish and optimize a target-specific PET/CT imaging method for diagnosing digestive system malignancies. Patients will receive whole-body PET/CT scans after the injection of specific tracers, and the uptake of these tracers in tumors and normal tissues will be quantitatively assessed. The study will evaluate the diagnostic efficacy of these imaging agents by calculating various metrics such as sensitivity and specificity, and will also analyze the correlation between tracer uptake and protein expression levels in tumors. The ultimate goal is to determine the feasibility and preliminary diagnostic value of these imaging techniques for digestive system cancers.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-75 with a confirmed or suspected diagnosis of digestive system carcinoma.
Not a fit: Patients who are pregnant or have severe hepatic and renal insufficiency may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of diagnosing digestive system cancers, leading to better treatment decisions.
How similar studies have performed: Other studies have shown promise in using targeted imaging agents for cancer diagnosis, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged 18-75 years old and of either sex； 2. Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging; 3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol. Exclusion Criteria: 1. Pregnancy； 2. Severe hepatic and renal insufficiency; 3. History of serious surgery in the last month; 4. Allergic to antibody or single-domain antibody radiopharmaceuticals.
Where this trial is running
Shanghai, Shanghai Municipality
- Renji Hospital, School of Medicine, Shanghai Jiao Tong University — Shanghai, Shanghai Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Weijun Wei, Ph.D. & M.D.
- Email: wwei@shsmu.edu.cn
- Phone: 15000083153
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Malignancy, Digestive Cancer, Digestive System Neoplasm, Digestive System Carcinoma, Digestive System Cancer, Liver Cancer, Stomach Cancer, Colon Cancer